DISRUPT: A randomized phase 2 trial of ombrabulin (AVE8062) combined with a taxane-platinum regimen in the first-line treatment of metastatic non-small cell lung cancer (NSCLC)

Category Primary study
JournalPneumologie
Year 2013
This article has no abstract
Epistemonikos ID: 608b6efa2b060822d44a04a274296ee4a9be085f
First added on: Feb 05, 2025